Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173425 | 1.00 | TSHR (0.62) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL14710749 | 1.00 | TSHR (0.62) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| Bicarbonate SCHEMBL3225171 | 0.93 | TSHR (0.59) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| Bicarbonate SCHEMBL3225179 | 0.93 | TSHR (0.59) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| Bicarbonate SCHEMBL3225167 | 0.91 | TSHR (0.58) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL15057638 | 0.84 | TSHR (0.62) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL11727865 | 0.80 | CYP3A4 (0.62) | TSHRLMNASMN1; SMN2CES1PLAU | |
| SCHEMBL16930819 | 0.79 | TSHR (0.56) | TSHRLMNAGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL7353197 | 0.79 | CES1 (0.59) | TSHRLMNAGAAALDH1A1CES1 | |
| SCHEMBL8620473 | 0.79 | CES1 (0.59) | TSHRLMNAGAAALDH1A1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905263-B1 | 4-nitro-N′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound | King Faisal University (SA) | 2024-02-20 | — | — | US | claimed |
| US-11905264-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-nitrobenzimidamide as an antimicrobial compound | King Faisal University (SA) | 2024-02-20 | — | — | US | claimed |
| US-20250154115-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-05-15 | — | — | US | disclosed |
| CN-119320366-A | Substituted naphthalene methyl oxadiazole-aniline compound and application thereof | 中国医学科学院药物研究所 | 2025-01-17 | — | — | CN | disclosed |
| EP-4472959-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-12-11 | — | — | EP | disclosed |
| US-11905264-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-nitrobenzimidamide as an antimicrobial compound | King Faisal University (SA) | 2024-02-20 | — | — | US | disclosed |
| US-11905263-B1 | 4-nitro-N′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound | King Faisal University (SA) | 2024-02-20 | — | — | US | disclosed |
| EP-3256461-B1 | UREA AND SULFONAMIDE DERIVATIVES AS HUMAN HELICASE DDX3 INHIBITORS USEFUL IN THE TREATMENT OF VIRAL DISEASES | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023148481-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2023-08-10 | — | — | WO | disclosed |
| EP-3432881-B1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2021-11-24 | — | — | EP | disclosed |
| US-11161835-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20110196002-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED. | 2011-08-11 | — | — | US | disclosed |
| US-20110196002-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED. | 2011-08-11 | — | — | US | disclosed |
| WO-2010023609-A1 | OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-03-04 | — | — | WO | disclosed |
| EP-1373264-B1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-6821972-B2 | ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS | PFIZER INC. | 2004-11-23 | — | — | US | disclosed |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PFIZER INC. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905263-B1 | 4-nitro-N′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound | NIT2, B3GNT2, IL4I1 | TSHR 4609/4885LMNA 3481/4885GAA 936/4885 |
| US-20110196002-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, DLAT | TSHR 2305/4885LMNA 3819/4885GAA 317/4885 |
| US-11905264-B1 | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-nitrobenzimidamide as an antimicrobial compound | NIT2, B3GNT2, IL4I1 | TSHR 4542/4885LMNA 4416/4885GAA 1743/4885 |
| US-20250154115-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | PFKL, IP6K2, IP6K1 | TSHR 3905/4885LMNA 2476/4885GAA 3265/4885 |
| US-11161835-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | TSHR 2676/4885LMNA 3213/4885GAA 336/4885 |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PAH, CYP2F1, CYP7A1 | TSHR 4093/4885LMNA 1661/4885GAA 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.